High-Dose-Rate Brachytherapy for Prostate Cancer Recurrence
Official title: Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
Run by University Health Network, Toronto · NCT06508567 · Data updated 2026-11-12
This study is testing a new way to treat prostate cancer that has come back after previous radiation therapy, using a special type of targeted radiation guided by MRI to see if it helps patients feel better and improve their health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 20 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | August 8, 2024 |
| Main results expected | August 8, 2028 |
| Study ends | March 1, 2031 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT06508567 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men over 18 years old with biopsy-proven isolated prostate bed recurrence following previous radiotherapy.
✕Probably not a fit
Patients with evidence of distant metastases or significant prior gastrointestinal or genitourinary toxicities from radiotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial investigates the feasibility of using MR-guided High-Dose-Rate brachytherapy to treat prostate bed recurrence in patients who have previously undergone radiotherapy. Participants will receive two fractions of 13 Gy each, delivered over a period of 7 to 21 days, with treatment planning based on MRI and PSMA PET imaging. The study will assess patient outcomes through quality of life questionnaires, PSA levels, and imaging follow-ups over a 60-month period.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with recurrent prostate cancer after prior radiotherapy.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in localized treatment of recurrent prostate cancer, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who received previous RT to the prostate bed +/- pelvic nodal regions 2. Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan 3. At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl 4. With or without ADT PSA doubling time from nadir greater than 6 months 5. ECOG 0-2 6. Age greater than 18 years Exclusion Criteria: 1. Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases 2. History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT 3. Any contraindications to MR and/or brachytherapy
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Peter Chung, MD
- Email: peter.chung@uhn.ca
- Phone: 416-946-4501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How social, structural, and lifestyle factors relate to prostate cancer outcomes in diverse men
This study looks at whether social and lifestyle factors help explain differences in prostate cancer outcomes among Black, Hispanic, and Asian men who have had a radical prostatectomy.
-
Mini-tumors to guide treatment for aggressive prostate cancer
We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.
-
Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy
This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.
-
Treatment for recurrent prostate cancer with metastases
This study is testing whether combining hormone therapy with targeted radiation or surgery can help men with recurrent prostate cancer live longer without their cancer spreading.
-
Evaluating PSMA-PET/CT for Prostate Cancer Recurrence
This study is testing if using a special imaging technique called PSMA-PET/CT can help guide better treatment for men with prostate cancer who have had a rise in their PSA levels after surgery.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.